Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in Hormone Naive Recurrent or Metastatic Hormone Sensitive Prostate Cancer
NCT00095667Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2004
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in prostate cancer (PCa), sponsored by National Cancer Institute. Started Nov 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00095667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095667.